Biopolym. Cell. 2005; 21(3):287-292.
http://dx.doi.org/10.7124/bc.0006F4
Bioorganic Chemistry
Evaluation of 4H-4-chromenone derivatives as inhibitors of protein kinase CK2
1Prykhod'ko A. O., 1Yakovenko O. Ya., 1Golub A. G., 1Bdzhola V. G., 1Yarmoluk S. M.
  1. Institute of Molecular Biology and Genetics, NAS of Ukraine
    150, Akademika Zabolotnoho Str., Kyiv, Ukraine, 03680

Abstract

Protein kinase CK2 (Casein Kinase 2) is a ubiquitous serine/threonine protein kinase involved in various cell signal transduction pathways. Thus, CK2 is a new perspective target for anticancer drugs. The receptor-based virtual screening of 2000 compounds from combinatorial library of 4H-4-chromenones has been carried out in search for CK2-inhibitors. 90 compounds have been chosen for biological testing based on the score values calculated by DOCK 4.0 software. It has been revealed, that 3-(4-chloro-3,5-dimethylphenoxy)-7-(4-methoxyphenylcarbonyloxy)-4-oxo-4H-chromene (12) and 7-(4-fluorophenylcarbonyloxy)-4-oxo-3-(4-phenylphenoxy)-4H-chromene (14) inhibit CK2 activity with IC50= 18.8 mM and IC50=22.4 mM, respectively.
Keywords: receptor-based design, CK2 kinase inhibitor, 4H-4-chromenone, chromone
Full text: (PDF, in English)

References

[1] Murray AW. Recycling the cell cycle: cyclins revisited. Cell. 2004;116(2):221-34.
[2] Kimmich RD, Park WK. Chemical libraries towards protein kinase inhibitors. Comb Chem High Throughput Screen. 2003;6(7):661-72.
[3] Allende JE, Allende CC. Protein kinases. 4. Protein kinase CK2: an enzyme with multiple substrates and a puzzling regulation. FASEB J. 1995;9(5):313-23.
[4] Pinna LA. Protein kinase CK2. Int J Biochem Cell Biol. 1997;29(4):551-4.
[5] Marchiori F, Meggio F, Marin O, Borin G, Calderan A, Ruzza P, Pinna LA. Synthetic peptide substrates for casein kinase 2. Assessment of minimum structural requirements for phosphorylation. Biochim Biophys Acta. 1988;971(3):332-8.
[6] Marin O, Meggio F, Marchiori F, Borin G, Pinna LA. Site specificity of casein kinase-2 (TS) from rat liver cytosol. A study with model peptide substrates. Eur J Biochem. 1986;160(2):239-44.
[7] Seldin DC, Leder P. Casein kinase II alpha transgene-induced murine lymphoma: relation to theileriosis in cattle. Science. 1995;267(5199):894-7.
[8] Ravi R, Bedi A. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II. Cancer Res. 2002;62(15):4180-5.
[9] Cotelle N. Role of flavonoids in oxidative stress. Curr Top Med Chem. 2001;1(6):569-90.
[10] van Acker FA, Hageman JA, Haenen GR, van Der Vijgh WJ, Bast A, Menge WM. Synthesis of novel 3,7-substituted-2-(3',4'-dihydroxyphenyl)flavones with improved antioxidant activity. J Med Chem. 2000;43(20):3752-60.
[11] Owen RW, Giacosa A, Hull WE, Haubner R, Spiegelhalder B, Bartsch H. The antioxidant/anticancer potential of phenolic compounds isolated from olive oil. Eur J Cancer. 2000;36(10):1235-47.
[12] Jing Y, Waxman S. Structural requirements for differentiation-induction and growth-inhibition of mouse erythroleukemia cells by isoflavones. Anticancer Res. 1995;15(4):1147-52.
[13] Ren W, Qiao Z, Wang H, Zhu L, Zhang L, Lu Y, Cui Y, Zhang Z, Wang Z. Tartary buckwheat flavonoid activates caspase 3 and induces HL-60 cell apoptosis. Methods Find Exp Clin Pharmacol. 2001;23(8):427-32.
[14] Wenzel U, Kuntz S, Brendel MD, Daniel H. Dietary flavone is a potent apoptosis inducer in human colon carcinoma cells. Cancer Res. 2000;60(14):3823-31.
[15] Wang IK, Lin-Shiau SY, Lin JK. Induction of apoptosis by apigenin and related flavonoids through cytochrome c release and activation of caspase-9 and caspase-3 in leukaemia HL-60 cells. Eur J Cancer. 1999;35(10):1517-25.
[16] Ko WG, Kang TH, Lee SJ, Kim NY, Kim YC, Sohn DH, Lee BH. Polymethoxyflavonoids from Vitex rotundifolia inhibit proliferation by inducing apoptosis in human myeloid leukemia cells. Food Chem Toxicol. 2000;38(10):861-5.
[17] Traxler P, Green J, Mett H, S?quin U, Furet P. Use of a pharmacophore model for the design of EGFR tyrosine kinase inhibitors: isoflavones and 3-phenyl-4(1H)-quinolones. J Med Chem. 1999;42(6):1018-26.
[18] Geahlen RL, Koonchanok NM, McLaughlin JL, Pratt DE. Inhibition of protein-tyrosine kinase activity by flavanoids and related compounds. J Nat Prod. 1989;52(5):982-6.
[19] Cushman M, Nagarathnam D, Burg DL, Geahlen RL. Synthesis and protein-tyrosine kinase inhibitory activities of flavonoid analogues. J Med Chem. 1991;34(2):798-806.
[20] Srivastava AK. Inhibition of phosphorylase kinase, and tyrosine protein kinase activities by quercetin. Biochem Biophys Res Commun. 1985;131(1):1-5.
[21] L?pez-L?zaro M, Mart?n-Cordero C, Toro MV, Ayuso MJ. Flavonoids as DNA topoisomerase I poisons. J Enzyme Inhib Med Chem. 2002;17(1):25-9.
[22] L?pez-L?zaro M, Mart?n-Cordero C, Ayuso MJ. Two new flavonol glycosides as DNA topoisomerase I poisons. Z Naturforsch C. 2000;55(11-12):898-902.
[23] Gamet-Payrastre L, Manenti S, Gratacap MP, Tulliez J, Chap H, Payrastre B. Flavonoids and the inhibition of PKC and PI 3-kinase. Gen Pharmacol. 1999;32(3):279-86.
[24] Agullo G, Gamet-Payrastre L, Manenti S, Viala C, R?m?sy C, Chap H, Payrastre B. Relationship between flavonoid structure and inhibition of phosphatidylinositol 3-kinase: a comparison with tyrosine kinase and protein kinase C inhibition. Biochem Pharmacol. 1997;53(11):1649-57.
[25] Ferriola PC, Cody V, Middleton E Jr. Protein kinase C inhibition by plant flavonoids. Kinetic mechanisms and structure-activity relationships. Biochem Pharmacol. 1989;38(10):1617-24.
[26] Casagrande F, Darbon JM. Effects of structurally related flavonoids on cell cycle progression of human melanoma cells: regulation of cyclin-dependent kinases CDK2 and CDK1. Biochem Pharmacol. 2001;61(10):1205-15.
[27] Sarno S, Moro S, Meggio F, Zagotto G, Dal Ben D, Ghisellini P, Battistutta R, Zanotti G, Pinna LA. Toward the rational design of protein kinase casein kinase-2 inhibitors. Pharmacol Ther. 2002;93(2-3):159-68.
[28] Battistutta R, De Moliner E, Sarno S, Zanotti G, Pinna LA. Structural features underlying selective inhibition of protein kinase CK2 by ATP site-directed tetrabromo-2-benzotriazole. Protein Sci. 2001;10(11):2200-6.
[29] Battistutta R, Sarno S, De Moliner E, Papinutto E, Zanotti G, Pinna LA. The replacement of ATP by the competitive inhibitor emodin induces conformational modifications in the catalytic site of protein kinase CK2. J Biol Chem. 2000;275(38):29618-22.
[30] Filikov AV, James TL. Structure-based design of ligands for protein basic domains: application to the HIV-1 Tat protein. J Comput Aided Mol Des. 1998;12(3):229-40.
[31] Shoichet BK, Stroud RM, Santi DV, Kuntz ID, Perry KM. Structure-based discovery of inhibitors of thymidylate synthase. Science. 1993;259(5100):1445-50.
[32] Bodian DL, Yamasaki RB, Buswell RL, Stearns JF, White JM, Kuntz ID. Inhibition of the fusion-inducing conformational change of influenza hemagglutinin by benzoquinones and hydroquinones. Biochemistry. 1993;32(12):2967-78.
[33] Ring CS, Sun E, McKerrow JH, Lee GK, Rosenthal PJ, Kuntz ID, Cohen FE. Structure-based inhibitor design by using protein models for the development of antiparasitic agents. Proc Natl Acad Sci U S A. 1993;90(8):3583-7.
[34] Schmidt MW, Baldridge KK, Boatz JA, Elbert ST, Gordon MS, Jensen JH, Koseki S, Matsunaga N, Nguyen KA, Su S, Windus TL. The general atomic and molecular electronic structure system. J Comp Chem. 1993. 14: 1347-58.
[35] Lindahl E, Hess B, van der Spoel D. GROMACS 3.0: a package for molecular simulation and trajectory analysis. Mol Mod. 2001. 7: 306-17.
[36] Ewing TJA, Kuntz JD. Critical evaluation of search algorithms for automated molecular docking and database screening. J Comp Chem. 1996; 18(9):1175-89.
[37] Bursulaya BD, Totrov M, Abagyan R, Brooks CL 3rd. Comparative study of several algorithms for flexible ligand docking. J Comput Aided Mol Des. 2003;17(11):755-63.
[38] Vasil’ev SA, Luk’yanchikov MS, Molchanov GI, Turubarov VD, Khilya VP. Synthesis and biological properties of 3-phenoxchromones and 3-phenoxy-4-hydroxy-7-methoxycoumarin. Pharmaceutical Chemistry Journal. 1991;25(7):470–5.
[39] Arkhipov VV, Smirnov MN, Khilya VP. Chemistry of modified flavonoids. 19. Synthesis of phenoxyl analogs of isoflavone. Chem Heterocycl Comp. 1997; 359: 598-603.
[40] Garazd MM, Arkhipov VV, Proskurka NK, Khilya VP. Chemistry of isoflavonoid hetero analogs. 23. Synthesis of aminoacyl derivatives of 3-phenoxychromone. Chem Heterocyc Comp. 1999; 384: 744-748.
[41] De Moliner E, Moro S, Sarno S, Zagotto G, Zanotti G, Pinna LA, Battistutta R. Inhibition of protein kinase CK2 by anthraquinone-related compounds. A structural insight. J Biol Chem. 2003;278(3):1831-6.
[42] Sarno S, de Moliner E, Ruzzene M, Pagano MA, Battistutta R, Bain J, Fabbro D, Schoepfer J, Elliott M, Furet P, Meggio F, Zanotti G, Pinna LA. Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA). Biochem J. 2003;374(Pt 3):639-46.
[43] Vangrevelinghe E, Zimmermann K, Schoepfer J, Portmann R, Fabbro D, Furet P. Discovery of a potent and selective protein kinase CK2 inhibitor by high-throughput docking. J Med Chem. 2003;46(13):2656-62.